Trials / Recruiting
RecruitingNCT07123129
A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors
An Open-label, Multicenter Phase I Clinical Study of SHR-7782 Injection in the Treatment of Advanced Malignant Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the effectiveness and safety of SHR-7782 for participants with advanced malignant cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-7782 Injection | SHR-7782 injection. |
Timeline
- Start date
- 2025-08-28
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2025-08-14
- Last updated
- 2026-01-30
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07123129. Inclusion in this directory is not an endorsement.